Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sun Pharmaceuticals Industries's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 68.83%.
The historical rank and industry rank for Sun Pharmaceuticals Industries's ROC (Joel Greenblatt) % or its related term are showing as below:
BOM:524715'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.35 Med: 37.5 Max: 70.38
Current: 70.38
During the past 13 years, Sun Pharmaceuticals Industries's highest ROC (Joel Greenblatt) % was 70.38%. The lowest was 14.35%. And the median was 37.50%.
BOM:524715's ROC (Joel Greenblatt) % is ranked better than 90.44% of 983
companies
in the Drug Manufacturers industry
Industry Median: 10.44
vs BOM:524715: 70.38
Sun Pharmaceuticals Industries (BOM:524715) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharmaceuticals Industries ROC (Joel Greenblatt) % Chart
BOM:524715 vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharmaceuticals Industries's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharmaceuticals Industries ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharmaceuticals Industries's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sun Pharmaceuticals Industries's ROC (Joel Greenblatt) % falls into.
Sun Pharmaceuticals Industries ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 68.83% mean?
Sun Pharmaceuticals Industries (BOM:524715) has a ROC (Joel Greenblatt) % of 68.83% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sun Pharmaceuticals Industries and its competitors. This is 84% above median its historical median of 37.50. Over the past decade, Sun Pharmaceuticals Industries' ROC (Joel Greenblatt) % has ranged from 14.35 to 70.38. According to the industry distribution chart, Sun Pharmaceuticals Industries ranks #94 out of 983 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is Sun Pharmaceuticals Industries' ROC (Joel Greenblatt) % too high?
Sun Pharmaceuticals Industries' current ROC (Joel Greenblatt) % of 68.83% is 84% above median its 10-year median of 37.50. Over the past 10 years, this metric has ranged from a low of 14.35 to a high of 70.38. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 10.44. Sun Pharmaceuticals Industries' value of 68.83% is 559.3% above this industry median. Based on the distribution chart, Sun Pharmaceuticals Industries ranks #94 out of 983 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharmaceuticals Industries has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharmaceuticals Industries' ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharmaceuticals Industries ranks #94 out of 983 companies for ROC (Joel Greenblatt) %. This places Sun Pharmaceuticals Industries in the top 10% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 10.44. Sun Pharmaceuticals Industries' value of 68.83% is 559.3% above this benchmark. Historically, Sun Pharmaceuticals Industries' own ROC (Joel Greenblatt) % has ranged from 14.35 to 70.38 over the past decade. While the company's 10-year median is 37.50 vs. the industry median of 10.44, Sun Pharmaceuticals Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 10.44, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharmaceuticals Industries's current ROC (Joel Greenblatt) % of 68.83% is 559.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sun Pharmaceuticals Industries and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 10.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharmaceuticals Industries's current ROC (Joel Greenblatt) % is 68.83%, which is 84% above median its own 10-year median of 37.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharmaceuticals Industries stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries (BOM:524715) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,969.26, compared to a current price of ₹1,842.00 — trading 6.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 68.83%, which is 84% above median its 10-year median of 37.50 and 559.3% above the Drug Manufacturers industry median of 10.44. Sun Pharmaceuticals Industries' overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sun Pharmaceuticals Industries (BOM:524715), the current ROC (Joel Greenblatt) % is 68.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharmaceuticals Industries (BOM:524715) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries stock appears to be undervalued.
The current stock price of ₹1,842.00 is trading 6.5% below its estimated GF Value™ of ₹1,969.26.
GuruFocus considers Sun Pharmaceuticals Industries to be Fairly Valued.
Key valuation signals for BOM:524715:
ROC (Joel Greenblatt) %: 68.83% (84% above median its 10-year median of 37.50)
GF Value™: ₹1,969.26 vs. price of ₹1,842.00 (6.5% below fair value)
Industry Position: 559.3% above the Drug Manufacturers median (#94 of 983)
No single metric tells the full story. See the BOM:524715 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company's substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
91GF Score
Get the complete analysis for BOM:524715
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524715 has been successfully added to your 
